CR20200124A - Inhibidores macrocíclicos de mcl-1 y métodos de uso - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso

Info

Publication number
CR20200124A
CR20200124A CR20200124A CR20200124A CR20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
methods
mcl
macrocyclic
compounds
Prior art date
Application number
CR20200124A
Other languages
English (en)
Inventor
Wilfried Braje
Andrew Souers
Gerard Sullivan
Michael Wendt
Thomas Penning
Andrew Judd
Cheng Ji
Xiaohong Song
Zhi-Fu Tao
Anthony Mastracchio
Jesse Teske
Katja Jantos
Aaron Kunzer
Frauke Pohlki
George Doherty
Chunqiu Lai
Xilu Wang
Andreas Kling
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of CR20200124A publication Critical patent/CR20200124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación proporciona compuestos de la Fórmula (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
CR20200124A 2017-08-15 2018-08-15 Inhibidores macrocíclicos de mcl-1 y métodos de uso CR20200124A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30
PCT/US2018/000180 WO2019035911A1 (en) 2017-08-15 2018-08-15 MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CR20200124A true CR20200124A (es) 2020-09-28

Family

ID=65362347

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200124A CR20200124A (es) 2017-08-15 2018-08-15 Inhibidores macrocíclicos de mcl-1 y métodos de uso

Country Status (21)

Country Link
US (3) US10676485B2 (es)
EP (2) EP3652184A4 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG10202106345VA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200239494A1 (en) * 2017-08-15 2020-07-30 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
ES2905100T3 (es) 2017-08-15 2022-04-07 Agios Pharmaceuticals Inc Activadores de piruvato quinasa para su uso en el tratamiento de trastornos sanguíneos
JP2020531436A (ja) * 2017-08-15 2020-11-05 アッヴィ・インコーポレイテッド 大環状ｍｃｌ−１阻害剤及び使用の方法
EP3652184A4 (en) * 2017-08-15 2020-05-20 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHOD FOR USE
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CA3074641A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
JP2022533400A (ja) 2019-05-20 2022-07-22 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
AU2022291381A1 (en) 2021-06-11 2023-11-30 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014627B (zh) * 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA44721B1 (fr) 2016-04-22 2020-05-29 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
WO2018078064A1 (en) 2016-10-28 2018-05-03 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer
EP3567043B1 (en) 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
JP2020531436A (ja) 2017-08-15 2020-11-05 アッヴィ・インコーポレイテッド 大環状ｍｃｌ−１阻害剤及び使用の方法
EP3652184A4 (en) * 2017-08-15 2020-05-20 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHOD FOR USE
US20200239494A1 (en) * 2017-08-15 2020-07-30 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Also Published As

Publication number Publication date
US20230183261A1 (en) 2023-06-15
PH12020500327A1 (en) 2020-10-12
ECSP20018703A (es) 2020-04-22
TW201920194A (zh) 2019-06-01
CL2020002943A1 (es) 2021-03-12
US20190144465A1 (en) 2019-05-16
KR20200041942A (ko) 2020-04-22
MX2020001717A (es) 2020-10-08
CO2020002678A2 (es) 2020-08-10
RU2020110517A3 (es) 2022-03-23
EP3652184A1 (en) 2020-05-20
BR112020003180A2 (pt) 2020-09-15
CL2020000363A1 (es) 2020-06-12
RU2020110517A (ru) 2021-09-16
CN111818917A (zh) 2020-10-23
EP3652184A4 (en) 2020-05-20
US10676485B2 (en) 2020-06-09
JP2020531433A (ja) 2020-11-05
UY37843A (es) 2019-03-29
EP3988555A1 (en) 2022-04-27
SG10202106345VA (en) 2021-07-29
IL272681A (en) 2020-03-31
SG11202001182QA (en) 2020-03-30
US20200325153A1 (en) 2020-10-15
CA3073112A1 (en) 2019-02-21
AU2018316620A1 (en) 2020-03-12
WO2019035911A1 (en) 2019-02-21
UA126586C2 (uk) 2022-11-02

Similar Documents

Publication Publication Date Title
PH12020500327A1 (en) Macrocyclic mcl-1 inhibitors and methods of use
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
PH12018501920A1 (en) Bromodomain inhibitors
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12015502852A1 (en) Bromodomain inhibitor
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
EA033689B9 (ru) Ингибиторы g12c kras
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2015012005A (es) Inhibidores de bromodominio.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12014501469A1 (en) Bromodomain inhibitors
MX2016007440A (es) Inhibidores del bromodominio.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019004187A (es) Inhibidores de bromodominios.
MX2019004375A (es) Inhibidores de bromodominios.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.